EYE INFLAMMATION TREATMENT MARKET ANALYSIS

Eye Inflammation Treatment Market, By Drug Class (Corticosteroids, Antibiotics, Monoclonal Antibodies, Antifungals, Cycloplegic Agents, and Others), By Dosage Form (Eye Drops, Tablets, Capsules, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

On September 16, 2024, Eyenovia, a pharmaceutical company, announced the launch of clobetasol propionate ophthalmic suspension 0.05% in the U.S. This medication is designed to manage postoperative eye inflammation treatment and pain following ocular surgeries, marking a significant advancement in eye care.
On March 4, 2024, Formosa Pharmaceuticals, Inc., a Taiwan-based pharmaceutical company, and AimMax Therapeutics, a U.S. biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved clobetasol propionate ophthalmic suspension 0.05% (APP13007) for treating post-operative inflammation and pain following ocular surgery
In June 2023, Novartis AG, global pharmaceutical company, announced an agreement to divest its 'front of eye' ophthalmology assets to Bausch + Lomb, a global eye health company. This agreement includes Xiidra, the U.S. FDA first approved prescription treatment for the signs and symptoms of dry eye disease, as well as the investigational drug SAF312 (libvatrep), which is being developed as a first-in-class therapy for chronic ocular surface pain (COSP)